Abstract:Introduction and objectives: The Prostate Imaging Reporting and Data System (PI-RADS) score reports the likelihood of a clinically significant prostate cancer (CsPCa) based on various multiparametric prostate magnetic resonance imaging (mpMRI) characteristics. The PI-RADS category 3 is an intermediate status, with an equivocal risk of malignancy. The PSA density (PSAD) has been proposed as a tool to facilitate biopsy decisions on PI-RADS category 3 lesions. The objective of this study is to determine the frequency of CsPCa, assess the diagnostic value of targeted biopsy and identify clinical predictors to improve the CsPCa detection rate in PI-RADS category 3 lesions. Methods: Between 1st January 2017 and 31st December 2022, a total of 1661 men underwent a prostate biopsy at our institution. Clinical and mpMRI data of men with PI-RADS 3 lesions was reviewed. The study population was divided into two groups: target group, including those submitted to systematic plus targeted biopsy versus non-target group when only systematic or saturation biopsy were performed. Patients with PI-RADS 3 lesions were divided into three categories based on pathological biopsy results: benign, clinically insignificant disease (score Gleason = 6 or International Society of Urologic Pathologic (ISUP) 1) and clinically significant cancer (score Gleason ≥ 7 (3+4) or ISUP ≥ 2) according to target and non-target group. Univariate and multivariate analyses were performed to identify clinical predictors to improve the CsPCa detection rate in PI-RADS category 3 lesions. Results: A total of 130 men with PIRADS 3 index lesions were identified. Pathologic results were benign in 77 lesions (59.2%), 19 (14.6%) were clinically insignificant (Gleason score 6) and 34 (26.2%) were clinically significant (Gleason score 7 or higher). Eighty-seven of the patients were included in the target group (66.9%) and 43 in the non-target group (33.1%). The CsPCa detection was higher in the non-target group (32.6%, n = 14 vs 23.0%, n = 20 respectively). When systematic and target biopsies were jointly performed, if the results of systematic biopsies are not considered and only the results of target biopsies are taken into account, a CsPCa diagnosis would be missed on 9 patients. The differences of insignificant cancer and CsPCa rates among the target or non-target group were not statistically significant (p = 0.50 and p = 0.24, respectively). on multivariate analysis, the abnormal DRE and lesions localized in Peripheral zone (PZ) were significantly associated with a presence of CsPCa in PI-RADS 3 lesions (oR = 3.61, 95% CI [1.22,10.72], p = 0.02 and oR = 3.31, 95% CI [1.35, 8.11], p = 0.01, respectively). A higher median PSAD significantly predisposed for CsPCa on univariate analyses (p = 0.05), however, was not significant in the multivariate analysis (p = 0.76). In our population, using 0.10 ng/ml/ml as a cut-off to perform biopsy, 41 patients would have avoided biopsy (31.5%), but 5 cases of CsPCa would not have been detected (3.4%). We could not identify any statistical significance between other clinical and imagiological variables and CsPCa detection. Conclusions: PI-RADS 3 lesions were associated with a low likelihood of CsPCa detection. A systematic biopsy associated or not with target biopsy is essential in PI-RADS 3 lesions, and targeted biopsy did not demonstrate to be superior in the detection of CsPCa. The presence of abnormal DRE and lesions localized in PZ potentially predict the presence of CsPCa in biopsied PI-RADS 3 lesions.

Cutoff Values of Prostate Imaging Reporting and Data System Version 2.1 Score in Men with Prostate-specific Antigen Level 4 to 10 Ng/ml: Importance of Lesion Location.

Improving the Detection Rate of Prostate Cancer in the Gray Zone of PI-RADS V2 and Serum Tpsa by Using Prostate-Specific Antigen–age Volume

Optimizing Prostate Cancer Accumulating Model: Combined PI-RADS V2 with Prostate Specific Antigen and Its Derivative Data.

Prostate Imaging-Reporting and Data System Version 2 in Combination with Clinical Parameters for Prostate Cancer Detection: a Single Center Experience

The Value of the Prostate Imaging Reporting and Data System Version 2 for the Diagnosis of Prostate Cancer

The Role of PSA Density among PI-RADS v2.1 Categories to Avoid an Unnecessary Transition Zone Biopsy in Patients with PSA 4-20 ng/mL

Assessment of Prostate Imaging Reporting and Data System Version 2.1 False-Positive Category 4 and 5 Lesions in Clinically Significant Prostate Cancer

Clinical and Radiological Factors for Predicting Clinically Significant Prostate Cancer in Biopsy-Naive Patients With PI-RADS 3 Lesions

The Value of PI-RADS v2.1 Combined with PSAD Stratification in Predicting Peripheral Zone Clinically Significant Prostate Cancer in Patients with PSA 4-20 ng/mL

Combining Clinical Parameters and Multiparametric Magnetic Resonance Imaging to Stratify Biopsy-Naïve Men for an Optimum Diagnostic Strategy with Prostate-Specific Antigen 4 Ng Ml−1 to 10 Ng Ml−1

Diagnostic Value of Prostate Imaging Reporting and Data System Version 1 and 2 in Detection of Prostate Cancer in Transition Zone

Pathological characteristics and predictive factors of prostate biopsy in patients with serum PSA levels between 0 and 4.0 ng/ml

MP53-05 CLINICALLY SIGNIFICANT PROSTATE CANCER DETECTION RATE OF PROSTATE IMAGING REPORTING AND DATA SYSTEM SCORE 4 IN THE PERIPHERAL ZONE

Can Prostate Imaging Reporting and Data System Version 2 Reduce Unnecessary Prostate Biopsies in Men with PSA Levels of 4–10 Ng/ml?

[Analysis of the relationship between PI-RADS scores and the pathological results of targeted biopsy based on MRI]

The Diagnostic Value of PI-RADS V1 and V2 Using Multiparametric MRI in Transition Zone Prostate Clinical Cancer

Predictors of prostate cancer detection in MRI PI-RADS 3 lesions - Reality of a tertiary center

Risk factor analysis and optimal cutoff value selection of PSAD for diagnosing clinically significant prostate cancer in patients with negative mpMRI: results from a high-volume center in Southeast China

PSA Density and Lesion Volume: Key Factors in Avoiding Unnecessary Biopsies for PI‐RADS 3 Lesions

Establishment of Two New Predictive Models for Prostate Cancer to Determine Whether to Require Prostate Biopsy when the PSA Level is in the Diagnostic Gray Zone (4–10 Ng Ml−1)

[The Clinical Decision-Making Value of Prostate Specific Antigen and Its Derived Indicators in Prostate Imaging Reporting and Data System Version 2 3 Lesions].